| Literature DB >> 27486520 |
Alex L Barwick1, John W Tessier1, Xanne Janse de Jonge2, James R Ivers1, Vivienne H Chuter1.
Abstract
OBJECTIVE: This study examined whether the presence of peripheral sensory neuropathy or cardiac autonomic deficits is associated with postocclusive reactive hyperemia (reflective of microvascular function) in the diabetic foot. RESEARCH DESIGN AND METHODS: 99 participants with type 2 diabetes were recruited into this cross-sectional study. The presence of peripheral sensory neuropathy was determined with standard clinical tests and cardiac autonomic function was assessed with heart rate variation testing. Postocclusive reactive hyperemia was measured with laser Doppler in the hallux. Multiple hierarchical regression was performed to examine relationships between neuropathy and the peak perfusion following occlusion and the time to reach this peak.Entities:
Keywords: Microvascular; Neuropathy; Neuropathy Complications; Neuropathy and Vascular Disease
Year: 2016 PMID: 27486520 PMCID: PMC4947724 DOI: 10.1136/bmjdrc-2016-000235
Source DB: PubMed Journal: BMJ Open Diabetes Res Care ISSN: 2052-4897
Figure 1Typical PORH response measured in perfusion units—channel 1 and cuff pressure—channel 2. PORH, postocclusive reactive hyperemia.
Participant characteristics (n=99)
| Age (mean, SD) | 68.6 (9.56) |
| Gender (male/female) | 64/35 |
| Toe pressure (mean, SD) | 99.39 (31.45) |
| HbA1c (%) (mean, SD) | 7.26 (1.47) |
| HcA1c (mmol/mol) (mean, SD) | 55.8 (16.15) |
| BMI (mean, SD) | 34 (7.42) |
| Retinopathy (past and current) (present/absent) | 7/92 |
| Sensory neuropathy (present/absent) | 41/58 |
| Diabetes duration | 11.72 (9.73) |
BMI, body mass index; HbA1c, glycated hemoglobin.
Regression analyses of sensory neuropathy with PORH
| R2 change | β | p Value | |
|---|---|---|---|
| TtP | |||
| Step 1* | 0.18 | <0.01 | |
| Step 2* | 0.22 | 0.03 | |
| Duration | −0.05 | 0.60 | |
| Age | 0.05 | 0.58 | |
| Gender* | −0.44 | 0.00 | |
| Sensory neuropathy* | 0.21 | 0.03 | |
| P%BL | |||
| Step 1 | 0.03 | 0.12 | |
| Step 2 | 0.02 | 0.68 | |
| Duration | −0.16 | 0.12 | |
| Age | −0.03 | 0.76 | |
| Gender | 0.21 | 0.06 | |
| Sensory neuropathy | 0.04 | 0.41 | |
*Significant at p<0.05.
P%BL, peak as a percentage of baseline; PORH, postocclusive reactive hyperemia; TtP, time to peak.
Regression analyses of autonomic neuropathy variables with PORH
| R2 change | β | p Value | |
|---|---|---|---|
| TtP | |||
| Step 1* | 0.18 | <0.01 | |
| Step 2 | 0.02 | 0.15 | |
| Duration | −0.05 | 0.60 | |
| Age* | −0.41 | <0.01 | |
| Gender | 0.002 | 0.98 | |
| RMS-SD | −0.14 | 0.15 | |
| P%BL | |||
| Step 1 | 0.06 | 0.12 | |
| Step 2 | 0.006 | 0.45 | |
| Duration | −0.16 | 0.14 | |
| Age* | 0.22 | 0.04 | |
| Gender | −0.03 | 0.75 | |
| RMS-SD | 0.08 | 0.45 | |
| TtP | |||
| Step 1* | 0.18 | <0.01 | |
| Step 2 | 0.02 | 0.13 | |
| Duration | −0.06 | 0.56 | |
| Age* | −0.41 | <0.01 | |
| Gender | 0.01 | 0.90 | |
| SDNN | −0.15 | 0.13 | |
| P%BL | |||
| Step 1 | 0.06 | 0.12 | |
| Step 2 | 0.005 | 0.48 | |
| Duration | −0.15 | 0.15 | |
| Age* | 0.22 | 0.04 | |
| Gender | −0.04 | 0.70 | |
| SDNN | 0.07 | 0.48 | |
| TtP | |||
| Step 1* | 0.18 | <0.01 | |
| Step 2 | 0.001 | 0.76 | |
| Duration | −0.04 | 0.67 | |
| Age* | −0.41 | <0.01 | |
| Gender | 0.01 | 0.89 | |
| Total power | −0.03 | 0.76 | |
| P%BL | |||
| Step 1 | 0.06 | 0.12 | |
| Step 2 | 0.001 | 0.83 | |
| Duration | −0.16 | 0.13 | |
| Age* | 0.22 | 0.04 | |
| Gender | −0.04 | 0.70 | |
| Total power | 0.02 | 0.83 | |
*Significant at p<0.05.
P%BL, peak as a percentage of baseline; PORH, postocclusive reactive hyperemia; RMS-SD, root mean square of the R–R interval; SDNN, SD of the N–N interval; TtP, time to peak.